DekaBank Deutsche Girozentrale Grows Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

DekaBank Deutsche Girozentrale grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 47.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 78,129 shares of the company’s stock after acquiring an additional 25,000 shares during the period. DekaBank Deutsche Girozentrale owned about 0.09% of Intellia Therapeutics worth $2,497,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Trust Inc. purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $26,000. Sandia Investment Management LP purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $35,000. Jefferies Financial Group Inc. purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $38,000. ICA Group Wealth Management LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $62,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Intellia Therapeutics by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock worth $72,000 after buying an additional 1,108 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NTLA shares. Wedbush reaffirmed a “neutral” rating and set a $29.00 target price on shares of Intellia Therapeutics in a research note on Thursday, February 15th. The Goldman Sachs Group downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. Wolfe Research started coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Canaccord Genuity Group boosted their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Intellia Therapeutics Trading Down 3.0 %

Shares of Intellia Therapeutics stock opened at $24.27 on Friday. The company has a fifty day simple moving average of $27.69 and a 200-day simple moving average of $28.20. Intellia Therapeutics, Inc. has a 12-month low of $22.67 and a 12-month high of $47.48. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -4.49 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The business had revenue of ($1.92) million during the quarter, compared to analysts’ expectations of $15.10 million. During the same quarter in the prior year, the business posted ($1.40) EPS. On average, analysts forecast that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the transaction, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.00% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.